BibTex RIS Cite

Proceedings in oncology: Aren’t we back to the future?

Year 2015, , 1 - 2, 30.09.2015

Perran Fulden Yumuk

https://doi.org/10.5472/mmj.37882

Abstract

Three weeks ago Pamir Atagunduz, the Chief Editor of
Marmara Medical Journal, talked to me about his plans for
the Journal in the upcoming years with great excitement
and enthusiasm. I felt honored when he asked if I would
be interested in becoming the invited editor for the first of
the “Special Issue” series of Marmara Medical Journal. The
same day I started to plan how to accomplish an oncology
issue in a very short period of time. When I called Esra
Saglam, asking for a review due in 3 weeks, not only she
said yes, but also encouraged me with her great ideas. Here,
I would especially thank to all of the authors in this issue for
writing these manuscripts despite their very busy schedule.
Also, I owe special thanks to Bruce Minsky for his positive
approach in contributing to our Journal.
In addition to the current information regarding positive
interaction between immunotherapy and radiotherapy you
will find the latest developments on treatment of various
cancers in this “Special Issue - Oncology “.

Keywords

-

References

  • References
  • Minsky B. Advances in the management of esophageal
  • cancer. Marmara Med J 2015; 28 (Special Issue 1):3-10.
  • doi:10.5472/mmj.10059
  • Dane F. What to expect from HER-2 directed therapies
  • in advanced gastric cancer? Marmara Med J 2015; 28
  • (Special Issue 1):11-15. doi:10.5472/mmj.87204
  • Akgun Z, Saglam EK. Neoadjuvant treatment in locally
  • advanced rectal cancer. Marmara Med J 2015; 28
  • (Special Issue 1):16-20. doi:10.5472/mmj.43321
  • Igdem S. Treatment of prostate cancer by hypofractionated
  • radiotherapy. Marmara Med J 2015; 28 (Special Issue
  • :21-23. doi:10.5472/mmj.11680
  • Bavbek S. How to approach castration-resistant prostate
  • cancer? Marmara Med J 2015; 28 (Special Issue 1):24-
  • doi:10.5472/mmj.80248
  • http://www.accessdata.fda.gov/drugsatfda_docs/
  • appletter/2015/207103Orig1s000ltr.pdf
  • Aktas B. CDK inhibitors in hormone receptor positive
  • advanced breast cancer. Marmara Med J 2015; 28
  • (Special Issue 1):35-39. doi:10.5472/mmj.77406
  • Anacak Y, Kamer S, Sert F. Combining radiotherapy with
  • immunotherapy. Marmara Med J 2015; 28 (Special Issue
  • :40-44. doi:10.5472/mmj.34632
  • ht tp: / /www.fda.gov/NewsEvents/Newsroom/
  • PressAnnouncements/ucm436534.htm
  • https://clinicaltrials.gov/ct2/show/NCT01642004?term
  • =CheckMate+017&rank=1
  • http://www.medscape.com/viewarticle/840890

-

Year 2015, , 1 - 2, 30.09.2015

Perran Fulden Yumuk

https://doi.org/10.5472/mmj.37882

Abstract

-

Keywords

-

References

  • References
  • Minsky B. Advances in the management of esophageal
  • cancer. Marmara Med J 2015; 28 (Special Issue 1):3-10.
  • doi:10.5472/mmj.10059
  • Dane F. What to expect from HER-2 directed therapies
  • in advanced gastric cancer? Marmara Med J 2015; 28
  • (Special Issue 1):11-15. doi:10.5472/mmj.87204
  • Akgun Z, Saglam EK. Neoadjuvant treatment in locally
  • advanced rectal cancer. Marmara Med J 2015; 28
  • (Special Issue 1):16-20. doi:10.5472/mmj.43321
  • Igdem S. Treatment of prostate cancer by hypofractionated
  • radiotherapy. Marmara Med J 2015; 28 (Special Issue
  • :21-23. doi:10.5472/mmj.11680
  • Bavbek S. How to approach castration-resistant prostate
  • cancer? Marmara Med J 2015; 28 (Special Issue 1):24-
  • doi:10.5472/mmj.80248
  • http://www.accessdata.fda.gov/drugsatfda_docs/
  • appletter/2015/207103Orig1s000ltr.pdf
  • Aktas B. CDK inhibitors in hormone receptor positive
  • advanced breast cancer. Marmara Med J 2015; 28
  • (Special Issue 1):35-39. doi:10.5472/mmj.77406
  • Anacak Y, Kamer S, Sert F. Combining radiotherapy with
  • immunotherapy. Marmara Med J 2015; 28 (Special Issue
  • :40-44. doi:10.5472/mmj.34632
  • ht tp: / /www.fda.gov/NewsEvents/Newsroom/
  • PressAnnouncements/ucm436534.htm
  • https://clinicaltrials.gov/ct2/show/NCT01642004?term
  • =CheckMate+017&rank=1
  • http://www.medscape.com/viewarticle/840890
There are 29 citations in total.

Details

Primary Language English
Journal Section Editorial
Authors

Perran Fulden Yumuk This is me

Publication Date September 30, 2015
Published in Issue Year 2015

Cite

APA Yumuk, P. F. (2015). Proceedings in oncology: Aren’t we back to the future?. Marmara Medical Journal, 28(1), 1-2. https://doi.org/10.5472/mmj.37882
AMA Yumuk PF. Proceedings in oncology: Aren’t we back to the future?. Marmara Med J. September 2015;28(1):1-2. doi:10.5472/mmj.37882
Chicago Yumuk, Perran Fulden. “Proceedings in Oncology: Aren’t We Back to the Future?”. Marmara Medical Journal 28, no. 1 (September 2015): 1-2. https://doi.org/10.5472/mmj.37882.
EndNote Yumuk PF (September 1, 2015) Proceedings in oncology: Aren’t we back to the future?. Marmara Medical Journal 28 1 1–2.
IEEE P. F. Yumuk, “Proceedings in oncology: Aren’t we back to the future?”, Marmara Med J, vol. 28, no. 1, pp. 1–2, 2015, doi: 10.5472/mmj.37882.
ISNAD Yumuk, Perran Fulden. “Proceedings in Oncology: Aren’t We Back to the Future?”. Marmara Medical Journal 28/1 (September 2015), 1-2. https://doi.org/10.5472/mmj.37882.
JAMA Yumuk PF. Proceedings in oncology: Aren’t we back to the future?. Marmara Med J. 2015;28:1–2.
MLA Yumuk, Perran Fulden. “Proceedings in Oncology: Aren’t We Back to the Future?”. Marmara Medical Journal, vol. 28, no. 1, 2015, pp. 1-2, doi:10.5472/mmj.37882.
Vancouver Yumuk PF. Proceedings in oncology: Aren’t we back to the future?. Marmara Med J. 2015;28(1):1-2.